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Abstract
Although melanoma vaccines stimulate tumor antigen (TA)-specific CD8+ T cells, objective
clinical responses are rarely observed. To investigate this discrepancy, we evaluated the character
of vaccine-induced CD8+ T cells with regard to the inhibitory T cell co-receptors PD-1 and Tim-3
in metastatic melanoma patients who were administered tumor vaccines. The vaccines included
incomplete Freund's adjuvant (IFA), CpG oligodeoxynucleotide (CpG) and the HLA-A2-restricted
analog peptide NY-ESO-1 157-165V, either by itself or in combination with the pan-DR epitope
NY-ESO-1 119-143. Both vaccines stimulated rapid TA-specific CD8+ T-cell responses detected
ex vivo, however, TA-specific CD8+ T cells produced more IFN-γ and exhibited higher lytic
function upon immunization with MHC class I and class II epitopes. Notably, the vast majority of
vaccine-induced CD8+ T cells upregulated PD-1 and a minority also upregulated Tim-3. Levels of
PD-1 and Tim-3 expression by vaccine-induced CD8+ T cells at the time of vaccine
administration correlated inversely with their expansion in vivo. Dual blockade of PD-1 and Tim-3
enhanced the expansion and cytokine production of vaccine-induced CD8+ T cells in vitro.
Collectively, our findings support the use of PD-1 and Tim-3 blockades with cancer vaccines to
stimulate potent antitumor T cell responses and increase the likelihood of clinical responses in
advanced melanoma patients.
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Introduction
Although peptide-based vaccines have failed to provide significant clinical benefits in
patients with advanced melanoma, the dissection of vaccine-induced T cell responses has
provided the rationale for stepwise optimization of vaccine strategies (1). A major
improvement of peptide vaccines with MHC class I epitopes and incomplete Freund’s
adjuvant (IFA) in cancer patients has been achieved by the addition of the TLR9 ligand
CpG-oligodeoxynucleotide (CpG) that stimulates strong tumor antigen (TA)-specific CD8+
T cell responses (2–4). Although the vaccine-induced CD8+ T cells are often tumor-reactive
in vitro, they fail to promote tumor rejection in patients with advanced melanoma. A number
of experimental studies have shown that CD4+ T cell depletion in mice with chronic
infections results in major CD8+ T cell dysfunction and disease progression, suggesting that
CD4+ T cell help plays a critical role in maintaining CD8+ T cell functions in the presence
of high antigen load (5–7). To determine whether TA-specific CD4+ T cells augment TA-
specific CD8+ T cell numbers and function in patients with advanced melanoma, two
clinical trials have compared immunizations with subcutaneous (SC) injections of MHC
class I epitopes versus both MHC class I and MHC class II epitopes, when emulsified in IFA
(8, 9). Strikingly, IFN-γ producing TA-specific CD8+ T cells were detected less frequently
in patients immunized with both class I and class II epitopes. These vaccines have not,
however, included potent adjuvants to activate APCs and prime strong vaccine-induced T
cells that can be detected ex vivo. Therefore, the immunological effect of CD4+ T cells in
patients with advanced melanoma still needs to be thoroughly evaluated in the context of
cancer vaccines with potent adjuvants.
A number of studies have shown that the inhibitory receptors PD-1 and Tim-3 are
upregulated by dysfunctional TA-specific CD8+ T cells in animals and patients with
advanced melanoma (10–12). Targeting PD-1 and Tim-3 with blocking antibodies enhances
the expansion and function of TA-specific CD8+ T cells in vitro and in vivo, resulting in
tumor rejection in experimental models. In animal models, PD-1 blockade synergizes with
tumor vaccines to enhance tumor antigen-specific T cell responses and induce delayed
tumor growth or partial tumor regression (13–15). In addition, vaccines appear to induce the
upregulation of PD-1 expression by vaccine-induced CD8+ T cells at tumor sites (14, 15).
PD-1 blockade alone represents one of the most potent therapies of advanced melanoma,
inducing durable complete and partial clinical responses in a significant number of
melanoma patients (16, 17). Whether PD-1 and Tim-3 are expressed by vaccine-induced
TA-specific CD8+ T cells and whether they play a role in regulating the expansion and
function of vaccine-induced CD8+ T cells in patients with advanced melanoma is still
unknown.
In this study, we present the immunological findings from a clinical trial of immunization
with IFA, CpG and the HLA-A2-restricted analog peptide NY-ESO-1 157-165V, either
alone, or in combination with the pan-DR epitope NY-ESO-1 119-143, in patients with
metastatic melanoma. We observed that the vast majority of vaccine-induced TA-specific
CD8+ T cells detected ex vivo upregulated PD-1 and that a minority also upregulated Tim-3.
The levels of PD-1 and Tim-3 expression by vaccine-induced CD8+ T cells at the time of
vaccine administration inversely correlated with their expansion in vivo. In addition, we
show that PD-1 and Tim-3 regulate the function and expansion of vaccine-induced CD8+ T
cells in vitro.
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Materials and Methods
Patients and study protocol
Twelve HLA-A2+ patients with NY-ESO-1+ stage III/IV melanoma (Supplementary Table
1) were included, after informed consent, in this phase I study approved by the University of
Pittsburgh Institutional Review Board. Each vaccine was prepared as a stable emulsion
composed of 2 mg CpG 7909/PF-3512676 (Pfizer Inc.), 400 μg analog peptide NY-ESO-1
157-165V alone (melanoma patient #1 [MP1] to MP5, in arm 1) or in combination with 400
μg peptide NY-ESO-1 119-143 (MP6 to MP12, in arm 2), in Montanide ISA-720 (Seppic
Inc.). The final immunization volume of 4 mL was administered as four separate SC
injections. Patients received 8 biweekly immunizations before clinical and immunological
evaluation after 4 months of treatment. Non-progressor patients received monthly
immunizations until disease progression.
Ex vivo frequency and phenotype analysis of NY-ESO-1 157-165-specific CD8+ T cells
CD8+ T lymphocytes were purified from PBMCs of patients using MACS Column
Technology (Miltenyi Biotec) and incubated with PE- or APC-labeled HLA-A2/NY-ESO-1
157-165, or HLA-A2/HIVpol 476-484 tetramers (LICR, Lausanne). Next, cells were surface
stained with the following antibodies: CD8-FITC or CD8-PerCP-Cy5.5, CD45RA-ECD or
CD14-ECD, CD19-ECD and CD56-biotin (Beckman Coulter) with streptavidin-ECD
(Invitrogen), CD4-PE-Cy7 (Beckman Coulter) or PD-1-PE-Cy7 (BioLegend) or CD28-
PerCp-Cy5.5 and CCR7-PE-Cy7 (BD Pharmingen), Tim-3-PE (R&D Systems) and CD27-
Alexa750 (eBioscience). A violet amine reactive dye (Invitrogen) was used to assess cell
viability. In some experiments, cells were intracellularly stained with Perforin-FITC (BD
Pharmingen), Granzyme A-Pacific Blue (Biolegend) and Granzyme B-APC (Invitrogen).
The lower limit of detection (LLD) of these assays, calculated as the mean percentage of
HIVpol 476-484 tetramer+ cells + 1.6445 x SD was estimated to be 0.001% of CD8+ T
cells.
Ex vivo intracellular cytokine and Foxp3 staining
Ex vivo cytokine production assays were performed as previously reported (18). Briefly,
purified CD8+ or CD4+ T cells were incubated with an equal number of non-CD3
autologous cells pulsed with either HLA-A2-restricted peptides NY-ESO-1 157-165 or
HIVpol 476-484, or pan-DR peptide NY-ESO-1 119-143 or peptide HIVpol 711-725 (10
μg/mL) prior to tetramer and/or cell surface staining, followed by intracellular cytokine
staining using IFN-γ-FITC, IL-2-APC, IL-4-PE (Miltenyi Biotec), TNF-Alexa700 or IL-21-
PE (BD Pharmingen) antibodies. A violet amine reactive dye (Invitrogen) was used to assess
the viability of the cells. Foxp3 staining was performed using a Foxp3 staining kit
(eBioscience). The LLD of cytokine-producing T cells, calculated as the mean percentage of
cells stained positively with isotype control antibodies for cytokine antibodies + 1.6445 x
SD was 0.001% of CD4+ or CD8+ T cells.
Ex vivo CD107a degranulation assays
Purified CD8+ T cells were incubated in the presence of non-CD3 autologous cells pulsed
with peptides NY-ESO-1 157-165 or HIVpol 476-484 (10 μg/mL), CD107a-FITC
antibodies (BD Pharmingen), brefeldin A and Monensin (Sigma-Aldrich), prior to tetramer
and cell surface staining with CD8-PerCP- Cy5.5, CD14-ECD, CD19-ECD, CD56-biotin,
CD4-PE-Cy7 (Beckman Coulter) antibodies and streptavidin-ECD.
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Experiments with PD-1 and Tim-3 blockade
The experiments with PD-1 and Tim-3 blockade were performed as previously described
(18).
Statistics
T cell responses to the vaccines were defined as greater than a 2-fold increase in the number
of tetramer+ T cells or NY-ESO-1-specific cytokine producing T cells at any time point after
starting immunization as compared to pre-vaccination and as greater than 2 times the LLD.
The Wilcoxon signed rank test was used to assess the significance of T cell responses. In
Figs. 3 and 4, a two-sided Student’s t-test was used to compare the two arms. In Figs. 5C
and 6A, a linear mixed model was used to determinate relationships between studied
variables. In PD-1 and Tim-3 blockade experiments, statistical hypotheses were tested with
the Wilcoxon signed rank test for paired results from the same patient. Tests were two-sided
and considered significant at P < 0.05.
Results
Immunization with MHC class I or class I and class II peptides results in rapid and strong
expansion of NY-ESO-1-specific CD8+ T cells
We first evaluated the ex vivo frequency of NY-ESO-1 157-165-specific CD8+ T cells
(hereafter also called NY-ESO-1-specific CD8+ T cells) in PBMCs collected from
melanoma patients prior to the first immunization and at different time points during the
course of vaccination. Immunization with MHC class I peptide (arm 1) or MHC class I and
class II peptides (arm 2) resulted in increased frequencies of NY-ESO-1-specific CD8+ T
cells that were detectable with HLA-A2/NY-ESO-1 157-165 (NY-ESO-1) tetramers ex vivo
in all patients after 2 immunizations (4 weeks of treatment) (Fig. 1 A-C). In patients with no
detectable NY-ESO-1-specific CD8+ T cells prior to therapy, the highest frequencies of
vaccine-induced NY-ESO-1-specific CD8+ T cells ranged from 0.011% to 0.19% of total
CD8+ T cells in arm 1, and from 0.022% to 0.82% in arm 2 (Fig. 1A and C). In two arm-1
patients (MP4 and MP5), and two arm-2 patients (MP11 and MP12), with spontaneous NY-
ESO-1-specific CD8+ T cells generated prior to the first vaccination, frequencies increased
from 4.21% and 0.021% of total CD8+ T cells to 7.73% (1.8-fold increase) and 0.17% (8.1-
fold increase), respectively, in arm 1, and from 0.018% and 0.028% of total CD8+ T cells to
0.094% (5.2-fold increase) and 0.31% (11.1-fold increase), respectively, in arm 2 (Fig. 1B
and C). Overall, we observed a significant increase in the frequencies of NY-ESO-1-specific
CD8+ T cells (P = 0.0005).
Collectively, our findings show that peptide vaccines with CpG, IFA and MHC class I
epitope alone and in combination with MHC class II epitope stimulate TA-specific CD8+ T
cells that are detectable ex vivo in patients with advanced melanoma.
Immunization with both MHC class I and class II peptides stimulates Th-1-type NY-ESO-1-
specific CD4+ T cells
We next evaluated the frequencies of NY-ESO-1 119-143-specific CD4+ T cells (hereafter
also called NY-ESO-1-specific CD4+ T cells) in PBMCs collected from melanoma patients
at different time points during the course of vaccination. To this end, we assessed the
frequencies of IFN-γ-producing CD4+ T cells that were detectable after ex vivo stimulation
with autologous non-CD3 cells pulsed with peptide NY-ESO-1 119-143. The seven patients
immunized with both MHC class I and class II peptides (arm 2) exhibited a rapid increase in
the frequencies of IFN-γ-producing NY-ESO-1-specific CD4+ T cells that reached a peak
after 8 to 12 weeks of vaccine therapy. In contrast, immunization with MHC class I peptide
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alone (arm1) had no effect on NY-ESO-1-specific CD4+ T cell expansion (Fig. 2A and B).
Notably, we observed a significant increase in the frequencies of NY-ESO-1-specific CD4+
T cells in arm-2 patients (P = 0.0156), whereas no significant increase was noted in arm-1
patients (P = 0.2500). Vaccine-induced NY-ESO-1-specific CD4+ T cells displayed a Th-1
phenotype, producing IFN-γ , TNF and IL-2, but no IL-4. They also produced IL-21 (Fig.
2C and Supplementary Figure S1). We observed that the percentage of CD25highFoxp3+
cells among vaccine-induced IFN-γ-producing NY-ESO-1-specific CD4+ T cells was very
low or undetectable (mean ± SD = 0.8% ± 1.1%), which is lower than that among total
CD4+ T cells (3.8% ± 2.4%) (Fig. 2D), suggesting that immunization with NY-ESO-1
119-143 MHC class II peptide, CpG and IFA preferentially induced CD4+ T helper cells.
Altogether, our data show that immunization with CpG, IFA and MHC class I and class II
peptides stimulated Th-1 type NY-ESO-1-specific CD4+ T cells that were detectable ex vivo
in melanoma patients.
Immunization with both MHC class I and class II peptides increases IFN-γ production,
cytolytic potential and lytic capacities of TA-specific CD8+ T cells
We next assessed the capability of NY-ESO-1 157-165-specific CD8+ T cells, in PBMCs
collected from melanoma patients, to produce cytokines (IFN-γ, TNF and IL-2), both before
and after 3 (MP5 only) or 4 months (all other patients) of vaccination. Ex vivo frequencies of
cytokine-producing NY-ESO-1-specific CD8+ T cells are presented in Fig. 3A,
Supplementary Fig. S2A and Supplementary Table 2. The increase in the percentages of
IFN-γ-producing cells, among total vaccine-induced NY-ESO-1-specific CD8+ T cells, was
significantly higher after vaccination in arm 2 (mean ± SD = 58.1% ± 22.2%) than in arm 1
(14.2% ± 29.3%). There was no significant difference for TNF and IL-2 production between
the two treatment arms (Fig. 3B).
We next assessed the intracellular expression of the cytotoxic molecules granzyme A
(GrzA), granzyme B (GrzB) and perforin (Perf) by NY-ESO-1-specific CD8+ T cells
present in PBMCs of patients, before and after 4 months of vaccination (3 months for MP5).
Ex vivo frequencies of GrzA+, GrzB+ and Perf + NY-ESO-1-specific CD8+ T cells are
presented in Fig. 4A, Supplementary Fig. S2B and Supplementary Table 3. The increase in
the expression of cytotoxic markers among vaccine-induced NY-ESO-1-specific CD8+ T
cells was significantly higher in patients immunized in arm 2 (mean ± SD = 67.4% ± 31.2%,
34.1% ± 28% and 25.5% ± 11.8%, for GrzA+, GrzB+ and Perf+ cells, respectively) than in
patients immunized in arm 1 (15.5% ± 17.9%, 3.9% ± 9.8% and 2.3% ± 6.9%, respectively)
(Fig. 4B). We also observed that the increase in the percentages of degranulating/CD107a+
cells among vaccine-induced NY-ESO-1-specific CD8+ T cells was significantly higher
after vaccination in arm 2 (mean ± SD = 42.2% ± 24.3%) than after vaccination in arm 1
(9.5% ± 15.7%), which shows that immunization with both MHC class I and class II
peptides enhanced lytic activity of TA-specific CD8+ T cells (Fig. 4C and D, Supplementary
Fig. S2C and Supplementary Table 3).
The expansion of vaccine-induced TA-specific CD8+ T cells correlates with the
upregulation of PD-1 and Tim-3 in vivo
We have previously reported that the inhibitory receptors PD-1 and Tim-3 play a critical
role in regulating the expansion and functions of spontaneous NY-ESO-1-specific CD8+ T
cells in vitro (12). We have also observed that PD-1 and Tim-3 upregulation by TA-specific
CD8+ T cells correlates with the expression of activation markers and can be further
increased upon TCR activation with cognate antigen in vitro (12, 18). To investigate
whether immunization with peptides and CpG promotes the upregulation of inhibitory
receptors, we next measured ex vivo expression of PD-1 and Tim-3 by vaccine-induced NY-
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ESO-1-specific CD8+ T cells at different time points during vaccine therapy (Fig. 5A and
B). We observed that PD-1 expression was upregulated by a vast majority of NY-ESO-1-
specific CD8+ T cells throughout the course of immunization in all arm-1 and arm-2
patients (mean ± SD %PD-1+ cells =73.3% ± 26%). In contrast, Tim-3 expression was
increased by a minority only of cells in 10 out of 12 patients (mean ± SD %Tim-3+ cells in
all patients =18.2% ± 16.3%). In all patients, a large majority of the Tim-3+ NY-ESO-1-
specific CD8+ T cells co-expressed PD-1 (mean ± SD %PD-1+ cells within Tim-3+ cells =
84.4% ± 12.2%; data not shown).
We next wanted to investigate whether the expansion of NY-ESO-1-specific CD8+ T cells
between immunizations correlated with changes in PD-1 and Tim-3 expression. We
therefore calculated both the fold changes in vaccine-induced NY-ESO-1-specific CD8+ T
cell frequencies and the differences in PD-1 and Tim-3 expression levels (differences in both
percentage and mean fluorescence intensity [MFI] of PD-1 and Tim-3 expression by NY-
ESO-1 tet+ CD8+ T cells) between two consecutive time points (corresponding to the two
nearest and consecutive available blood draws over 1 or 2- month intervals) throughout the
course of vaccination (up to 52 weeks) for each patient. We observed a positive correlation
between the fold change in vaccine-induced NY-ESO-1-specific CD8+ T cell frequencies
and the upregulation of PD-1 and Tim-3 (Fig. 5C), suggesting that the greater the vaccine-
induced CD8+ T cell expansion following immunization, the greater the levels of PD-1 and
Tim-3 expression.
The expansion of vaccine-induced TA-specific CD8+ T cells is regulated by PD-1 and Tim-3
We next investigated whether the expansion of vaccine-induced NY-ESO-1- specific CD8+
T cells between two consecutive time points (1- or 2-month intervals, up to 52 weeks of
vaccination), correlates with the level of PD-1 and Tim-3 expression at the time of
immunization. We observed a negative correlation between fold changes in vaccine-induced
NY-ESO-1-specific CD8+ T cell frequencies in vivo and the percentage of cells expressing
PD-1, or the MFI of cells expressing Tim-3 at the time of immunization (Fig. 6A). We next
evaluated the effects of PD-1 and Tim-3 pathway blockade on the expansion and function of
vaccine-induce TA-specific CD8+ T cells in vitro. CFSE-labeled PBMCs isolated from
eight melanoma patients after 4 months of vaccination (8 immunizations) were incubated for
6 days with NY-ESO-1 157-165 peptide in the presence of blocking mAbs against PD-1
and/or Tim-3 or IgG control antibodies. The frequencies of proliferating (CFSElo) and total
NY-ESO-1 tet+ CD8+ T cells increased after incubation with anti-PD-1, anti-Tim-3 or both
mAbs when compared to incubation with IgG control antibodies, resulting in 1.6-, 1.4- and
2.4-fold changes in the frequencies of CFSElo NY-ESO-1 157-165-specific CD8+ T cells,
respectively, and in 1.2-, 1.3- and 1.6-fold changes in the frequencies of total NY-ESO-1-
specific CD8+ T cells, respectively (Fig. 6B and C and Supplementary Figure S3), showing
an additive effect of PD-1 and Tim-3 blockades on vaccine-induced TA-specific CD8+ T
cell expansion.
In addition, the frequencies of vaccine-induced NY-ESO-1-specific CD8+ T cells that
produced cytokines increased after incubation in the presence of cognate peptide and anti-
PD-1 mAbs, when compared to IgG control antibodies, resulting in 1.6-fold, 1.6-fold and
1.8-fold changes in the frequencies of IFN-γ-, TNF- and IL-2-producing NY-ESO-1-specific
CD8+ T cells, respectively (Fig. 6D and E and Supplementary Figure S4). The frequencies
of cytokine-producing vaccine-induced NY-ESO-1-specific CD8+ T cells further increased
in the presence of both anti-PD-1 and anti-Tim-3 mAbs (Fig. 6D and E and Supplementary
Figure S4).
Collectively, our findings show that the levels of PD-1 and Tim-3 expression by vaccine-
induced TA-specific CD8+ T cells appear to be negatively correlated with the expansion of
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TA-specific CD8+ T cells in vivo following immunizations. They also show that PD-1 and
Tim-3 blockades further augment the expansion and cytokine production of vaccine-induced
TA-specific CD8+ T cells.
Side effects and clinical outcome
We observed no severe toxicity (Supplementary Table 4). None of the patients developed
objective clinical responses. Among the five patients immunized in arm 1, one patient
remained stable for 6 months, three patients progressed after 4 months and one patient
progressed after 3 months. Out of seven patients immunized in arm 2, two patients
progressed after 4 months while other patients remained stable for 6 months (2 patients), 7
months (one patient), 22 months (one patient) and 24 months (one patient) (Supplementary
Table 4).
Discussion
In this study, we report the capability of peptide vaccines with MHC class I or both MHC
class I and class II epitopes, in combination with CpG and IFA, to rapidly stimulate TA-
specific CD8+ T cells, which are detected ex vivo, in patients with advanced melanoma.
Notably, vaccine -induced TA-specific CD8+ T cells produced more IFN-γ and exhibited
higher cytotoxic potential and lytic functions in patients immunized with both MHC class I
and class II peptides when compared to MHC class I peptide alone, which supports a role for
CD4 T-cell help in enhancing antitumor CTL responses in vivo. These findings are in
agreement with a number of experimental studies of chronic viral infections in animal and
humans. Loss of CD4 T-cell help correlates with severe CD8+ T cell dysfunction and
disease progression (5, 6, 19), whereas adoptive transfer of LCMV-specific CD4+ T cells
into chronically infected mice enhances the function of exhausted CD8+ T cells (20). In
addition, in vivo stimulation of HIV-specific CD4+ T cells augments the
lymphoproliferative functions of HIV-specific CD8+ T cells in patients with chronic
infection (21).
The capability of cancer vaccines with CD4 helper epitopes to stimulate potent TA-specific
CD8+ T cell responses in patients with advanced melanoma remains elusive. To the best of
our knowledge, only two melanoma peptide vaccine trials have previously compared
immunization with MHC class I versus both MHC class I and class II epitopes. Phan et al.
immunized stage IV melanoma patients with HLA-A2-restricted peptides derived from
gp100 and Melan-A/MART-1, either alone or in combination with one gp100 HLA-DR4
peptide, in IFA. They detected TA-specific CD8+ T cell responses by IFN-γ ELISPOT after
in vitro sensitization assays in 18 of 19 patients immunized with MHC class I peptides
alone, and in 8 of 16 patients immunized with both MHC class I peptides and the HLA-DR4
peptide (8). In a large multicenter randomized trial, Slingluff et al immunized measurable
stage IV melanoma patients with 12 MHC class I peptides, alone or in combination with
either a T-helper tetanus peptide, or a mixture of MHC class II peptides, in IFA plus GM-
CSF(9). Strikingly, the response rates, as determined by IFN-γ ELISPOT after in vitro
sensitization, were lower in patients treated with both MHC class I and II peptides, than in
patients treated with MHC class I peptides, alone, or with MHC class I peptides in
combination with tetanus peptide. These investigators also reported that immune responses
to MHC class II epitopes were significantly associated with clinical responses and overall
survival. Although, the reasons behind the poor immunogenicity of these two peptide
vaccines with MHC class I and class II peptides in IFA have not been fully investigated, a
likely hypothesis is the stimulation of TA-specific Tregs in the absence of potent adjuvants.
We and others have previously reported that tumor antigens can spontaneously induce low
frequencies of TA-specific CD4+ Tregs in patients with advanced melanoma (22–24). It is
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therefore possible that peptide vaccines that do not include potent adjuvants expand TA-
specific Tregs. In this study, however, we show that CpG-based vaccine does not expand
CD25highFoxp3+ NY-ESO-1-specific CD4+ Tregs.
One critical finding is the upregulation of the inhibitory receptors PD-1 and Tim-3 by
vaccine-induced CD8 + T cells. We show that the majority of vaccine-induced CD8+ T cells
upregulate PD-1, while a minority also upregulate Tim-3. PD-1 and Tim-3 upregulation
correlates with the expansion of vaccine-induced CD8+ T cells following immunizations.
Therefore, the inhibitory receptors PD-1 and Tim-3, which are co-expressed by tumor-
induced exhausted CD8+ T cells present in patients with advanced cancer (12), are also
upregulated by freshly activated TA-specific CD8+ T cells primed by cancer vaccines. The
upregulation of PD-1 by vaccine-induced CD8+ T cells occurred in patients immunized with
MHC class I peptide, either alone or in combination with MHC class II peptide. This
suggests that while vaccine-induced TA-specific CD4+ T cells improve the functionality of
vaccine-induced TA-specific CD8+ T cells, they do not impede the upregulation of PD-1
and Tim-3 by these cells. Interestingly, the longitudinal evaluation of vaccine-induced CD8+
T cells throughout the course of immunizations showed that the levels of PD-1 and Tim-3
expression by vaccine-induced TA-specific CD8+ T cells at the time of immunization
inversely correlate with their expansion, suggesting that PD-1 and Tim-3 play a critical role
in regulating the expansion of vaccine-induced CD8+ T cells in vivo. In support of this
observation, we further show that PD-1 and Tim-3 blockades enhanced the expansion of
vaccine-induced TA-specific CD8+ T cells in vitro. In addition, while vaccination with both
MHC class I and class II peptides increased IFN-γ production by vaccine-induced CD8+ T
cells, PD-1 and Tim-3 blockades further augmented the frequency of IFN-γ-, TNF- and
IL-2-producing CD8+T cells, enhancing their overall functionality.
In summary, our data demonstrate that peptide vaccines with CpG, IFA and MHC class I
and class II peptides stimulate TA-specific CTLs with enhanced IFN-γ production, cytotoxic
potential and lytic capacities that upregulate PD-1 and Tim-3. They also show that PD-1 and
Tim-3 regulate the expansion of vaccine-induced CD8+ T cells throughout the course of
immunization and that PD-1 and Tim-3 blockades further enhance the expansion and
function of vaccine-induced CD8+ T cells. Altogether, these findings strongly support the
use of PD-1 and Tim-3 blockades, in combination with peptide vaccines and potent
adjuvant, for robust expansion of vaccine-induced TA-specific CTLs, and increased
likelihood of clinical benefits for patients with advanced melanoma. Such a therapeutic
strategy could prove useful to the melanoma patients who do not respond to anti-PD-1
antibody therapy alone, possibly due to the lack of spontaneous TA-specific CD8+ T cells at
tumor sites and PD-L1 expression by melanoma cells upon IFN-γ production by T cells (16,
25). Such patients may be more likely to respond favorably to the combination of PD-1 and
Tim-3 blockades with cancer vaccines.
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Figure 1.
Expansion of NY-ESO-1 157-165-specific CD8+ T cells following immunizations with
CpG, Montanide and MHC class I peptide, alone, or in combination with MHC class II
peptide. (A-B) Dot plots from total CD8+ T cells of selected melanoma patients (MP) in arm
1 (left panels) or in arm 2 (right panels) before and after vaccination. Data are the highest
reached percentages after vaccination for each patient. Numbers indicate percentages of ex
vivo detectable NY-ESO-1 tetramer (tet)+ CD8+ T cells among total CD8+ T cells. (C)
Kinetics of NY-ESO-1 tet+ cells among total CD8+ T cells throughout the course of
vaccination in all patients vaccinated in arm 1 (n = 5; left) and arm 2 (n = 7; right). Vertical
lines, time points of vaccinations. Data shown are from two independent experiments.
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Figure 2.
Immunization with MHC class II peptide stimulates Th-1-type NY-ESO-1-specific CD4+ T
cells. (A) Flow cytometry dot plots from total CD4+ T cells of one representative melanoma
patient in arm 2, before and after 4 months of vaccination, showing percentages of ex vivo
detectable IFN-γ-producing cells after incubation with autologous non-CD3 cells pulsed
with peptide NY-ESO-1 119-143 or an irrelevant peptide (HIVpol 711-725). (B) Kinetics of
ex vivo detectable IFN-γ + NY-ESO-1 119-143-specific CD4+ T cells among total CD4+ T
cells throughout the course of immunization in all patients vaccinated in arm 1 (n = 5; left)
and arm 2 (n = 7; right). Vertical lines, time points of vaccinations.(C) Summary data for
patients in arm 2 (n = 7) showing the frequencies of cytokine-producing NY-ESO-1
119-143-specific CD4+ T cells after 2 months of vaccination. (D) Dot plots from one
representative patient (left panel) and pooled data from seven patients (right panel) showing
the percentages of CD25highFoxp3+ cells within ex vivo detectable IFN-γ + and IFN-
γ −CD4+ T cells, after 4 months of vaccination in arm 2 and a short incubation with NY-
ESO-1 119-143 peptide. Data shown are from two independent experiments.
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Figure 3.
Immunization with MHC class I and class II peptides, CpG and Montanide increases
cytokine production by TA-specific CD8+ T cells. (A) Flow cytometry dot plots from total
CD8+ T cells of three selected melanoma patients (MP) in arm 1 (left panel) and arm 2
(right panel) showing the ex vivo percentages of IFN-γ - and IFN-γ + NY-ESO-1 157-165-
specific CD8+ T cells among total CD8+ T cells assessed after vaccination. (B) After-
versus before- vaccination differences in the percentages of IFN-γ-, TNF- and IL-2-
producing cells among total vaccine-induced NY-ESO-1-specific CD8+ T cells, in patients
immunized in arm 1 (n = 5) and arm 2 (n = 7). For patients with no NY-ESO-1-specific
CD8+ T cell response before vaccination, pre-vaccine percentages of cytokine-producing
cells were considered to be 0. Horizontal bars, means. Open circles, arm-1 patients, grey
circles, arm-2 patients. *, P < 0.05 was considered significant. Data shown are from two or
more independent measurements.
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Figure 4.
Immunization with MHC class I and class II peptides augments cytotoxic potential and lytic
function of TA-specific CTLs. (A) Flow cytometry dot plots of total CD8+ T cells from four
selected melanoma patients (MP) in arm 1 (left panel) and arm 2 (right panel), showing ex
vivo percentage of NY-ESO-1 tet+ CD8+ T cells among total CD8+ T cells that express
granzyme A, granzyme B, or perforin after vaccination. (B) After- versus before-
vaccination differences in the percentage of granzyme A, granzyme B and perforin-
expressing cells among total vaccine-induced NY-ESO-1-specific CD8+ T cells, in patients
from arm 1 (n = 5) and arm 2 (n = 7). For patients with no NY-ESO-1-specific CD8+ T cell
response before vaccination, pre-vaccine percentages of cytotoxic marker-expressing cells
were considered to be 0. (C) Flow cytometry dot plots of total CD8+ T cells from four
melanoma patients in arm 1 (left panel) and arm 2 (right panel), showing ex vivo
percentages of CD107a - and CD107a+ NY-ESO-1 tet+ CD8+ T cells among total CD8+ T
cells after vaccination. (D) After- versus before- vaccination differences in the percentages
of CD107a+ cells within total vaccine-induced NY-ESO-1-specific CD8+ T cells, in patients
from arm 1 (n = 5) and arm 2 (n = 7). Horizontal bars, means. Open circles, arm-1 patients,
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grey circles, arm-2 patients. *, P < 0.05 was considered significant. Data shown are from of
two independent experiments.
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Figure 5.
Ex vivo expression of PD-1 and Tim-3 by NY-ESO-1 157-165-specific CD8+ T cells
following immunizations in arms 1 and 2. (A-B) Flow cytometry dot plots from one selected
melanoma patient in arm 2 (MP6) (A), and summary data for all patients vaccinated in arm 1
(n = 5) and arm 2 (n = 7) (B), showing ex vivo percentages of PD-1+ and Tim-3+ cells within
total NY-ESO-1 tet+ CD8+ T cells, at different time points throughout the course of
vaccination. Vertical lines, time points of vaccinations. (C) Correlation between the fold
changes in NY-ESO-1 tet+ CD8+ T cell frequencies and the differences in ex vivo PD-1 and
Tim-3 expression (differences in percentage and MFI of PD-1 and Tim-3 expression by NY-
ESO-1 tet+ CD8+ T cells) throughout the course of vaccination. P < 0.05 was considered
significant. Data shown are from two independent experiments.
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Figure 6.
The expansion of vaccine-induced TA-specific CD8+ T cells is regulated by PD-1 and
Tim-3. (A) Correlation between the fold changes in NY-ESO-1 tet+ CD8+ T cell frequencies
assessed between two consecutive time points throughout the course of vaccination, in both
arms, and the level of PD-1 and Tim-3 expression (expressed as both percentage and MFI of
expression) by NY-ESO-1-specific CD8+ T cells assessed on the first day of each
corresponding interval, within each patient. P < 0.05 was considered significant. (B-E)
PBMCs isolated from eight melanoma patients after 4 months of vaccination (8
immunizations) were incubated for 6 days in vitro with peptide NY-ESO-1 157-165 in the
presence of blocking mAbs against PD-1 and/or Tim-3 or IgG control antibodies.
Frequencies and fold changes of proliferating/CFSElo or cytokine-producing NY-ESO-1-
specific CD8+ T cells were assessed after a 6-day IVS with cognate peptide and blocking
antibodies, compared to IgG control antibodies. (B-C) Representative flow cytometric
analysis from one melanoma patient, showing percentages of vaccine-induced CFSElo NY-
ESO-1 tet+ CD8+ T cells among total CD8+ T cells (B), and fold changes in the frequencies
of vaccine-induced CFSElo and total NY-ESO-1 tet+ CD8+ T cells (n = 8) (C). (D-E)
Representative flow cytometric analysis from one melanoma patient, showing percentages
of vaccine-induced IFN-γ-, TNF- and IL-2-producing NY-ESO-1 tet+ CD8+ T cells among
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total CD8+ T cells (D), and fold changes in the frequencies of vaccine-induced cytokine-
producing NY-ESO-1 tet+ CD8+ T cells (n = 8) (E). *, P < 0.05 was considered significant.
Horizontal bars, means. Data shown are representative of two independent experiments.
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